Form 4: Evommune Director Receives Stock Option Grant

Director Benjamin F. McGraw III was granted 15,673 stock options in Evommune, Inc. as part of standard equity compensation.

Summary

• Director Benjamin F. McGraw III received a grant of 15,673 stock options on June 2, 2026.
• The options have an exercise price of $19.82 per share.
• The options are set to expire on June 1, 2036.
• Vesting occurs on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $19.82 exercise price.

Future Outlook

The options vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, contingent upon continuous service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise.

Comparison to Industry Standards

• The grant structure and vesting schedule are consistent with standard corporate governance practices for mid-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on the earlier of June 2, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Evommune, EVMN, Director Compensation, Stock Options, Insider Transaction, Form 4